• Arcturus reported interim Phase 2 data showing ARCT-810 was generally safe, with fasting ammonia maintained in-range and glutamine reduced.
• LUNAR 2.0 delivery platform showed about 40-fold higher protein expression versus LUNAR 1.0 in non-human primates.
• Separate primate study showed LUNAR 2.0 delivered 38-fold higher hOTC expression potency than ARCT-810’s key lipid ATX-95.
• FDA feedback supports adding ARCT-2601, a LUNAR 2.0-based OTCD candidate, into the ongoing Phase 2 study near year-end for ages 12+.
• ARCT-2601 is expected to enable lower or less frequent dosing versus ARCT-810, based on non-human primate data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609231601BIZWIRE_USPR_____20260923_BW761420) on September 23, 2026, and is solely responsible for the information contained therein.